Screen Reader Access


C. B. Tripathi, Ph. D.

Scientist, Medicinal & Process Chemistry

Asymmetric Synthesis, Organocatalysis and Photocatalysis

Exploration of novel Reactivites and Catalysis

The prime focus of our lab is towards exploring new reactivities and concepts in the domain of catalysis and asymmetric synthesis. The protocols developed through these explorations are designed in a way to facilitate the drug discovery program on drug resistant tuberculosis. Moreover, we are also active in the domain of photocatalysis with a goal of developing general protocol for enantioselective radical reactions.

Asymmetric synthesis of medicinally active compounds is among the most sought after fields in organic synthesis. Over the years the field of asymmetric synthesis has flourished and via several activation modes a wide range of transformations have been developed. But despite the spectacular progress, the application of asymmetric synthesis in medicinal chemistry remains limited. This situation gets particularly challenging as a growing number of single enantiomers have been approved as drugs.

In the arena of organocatalysis our interest is in the field of enantioselective Brønsted acid catalysis. Over the last decade Brønsted acid catalysis has established itself as an important branch of organocatalysis. In 2004 Akiyama et al. and Terada et al. independently reported the application of BINOL derived phosphoric acids in asymmetric Mannich reaction. Since then several phosphoric acid derivatives are synthesized and numerous transformations have been accomplished by them relying on different activation modes. By utilizing these activation modes, we will attempt the asymmetric synthesis of several biologically relevant scaffolds with a quaternary chiral centre. The obtained compounds would be extrapolated to synthesize the library of compounds and their biological activities would be screened. In addition, we will also be active in the field of photocatalysis with a goal of developing new concepts and reactivities. In this domain our efforts will be focused towards developing a general protocol for enantioselective radical reactions. The synthetic methods developed will be utilized for synthesizing compounds with therapeutic relevance, particularly against drug resistant tuberculosis.